Table III:

Resistance factors in the three sublines of the R3327 prostate tumor model.

Heterogeneity factors	H-tumor	HI-tumor	AT1-tumor
Volume doubling time	≈20 days	≈10 days	≈5 days
Vascularization	Many big mature vessels	Big immature vessels	Less vessels, mostly immature
Number of CD31+-vessels	18.35 ± 0.85	22.93 ± 1.91*	17.31 ± 1.43
Vessel diameter [μm]	14.13 ± 0.26	14.14 ± 0.46	9.07 ± 0.28§
CD31+-area [%]	2.17 ± 0.23	4.06 ± 0.62$	2.45 ± 0.32
SMA+-area [%]	0.71 ± 0.11	0.01 ± 0.01&	0.34 ± 0.07
Amplitude weighted pO2 [torr]	136.0†	52.0†	14.0#
Hypoxic fraction [pO2 < 10 mmHg, HF10]	1 %	1.3 %	18 %
Subpopulations‡: aneuploidic cells	Diploid (DI 1.0: 33.5%), peridiploid (DI 1.07: 59.1%), hypotetraploid (DI 1.8: 7.3%)	Diploid (DI 1.0: 15.3%), peridiploid (DI 1.07: 82.2%), hypotetraploid (DI 1.8: 2.5%)	Diploid (DI 1.0: 66.5%), hypotetraploid (DI 1.8: 33.5%)
Subpopulations‡: potential stem cell marker (CD24, CD44, CD133, CD326)	2.9 – 8.0 % of cells	6.6 – 20.3 % of cells	15.3 – 24.6 % of cells

CD31− and SMA-staining are expressed in values ± SE. The amount of vessels was calculated as absolute number of CD31⁺-vessels per microscopic image (200x magnification). Aneuploidic tumor cells and potential stem cell markers were characterized by flow-cytometry.

^*Significant (p<0.05) relative to H- and AT1-tumor

^§Highly significant (p<0.0005) relative to H- and HI-tumor

^$Highly significant (p<0.0005) relative to H- and significant relative to AT1-tumor

^&Highly significant (p<0.0005) relative to H- and AT1-tumor

^‡DI: DNA-index, values cited from [42]

^†Animals breathing oxygen

^#Animals breathing air